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http://dx.doi.org/10.1016/j.ccr.2012.09.022SUMMARYEpithelial-mesenchymal transition (EMT) is implicated in converting stationary epithelial tumor cells into
motile mesenchymal cells during metastasis. However, the involvement of EMT in metastasis is still contro-
versial, due to the lack of a mesenchymal phenotype in human carcinoma metastases. Using a spontaneous
squamous cell carcinoma mouse model, we show that activation of the EMT-inducing transcription factor
Twist1 is sufficient to promote carcinoma cells to undergo EMT and disseminate into blood circulation.
Importantly, in distant sites, turning off Twist1 to allow reversion of EMT is essential for disseminated tumor
cells to proliferate and formmetastases. Our study demonstrates in vivo the requirement of ‘‘reversible EMT’’
in tumor metastasis and may resolve the controversy on the importance of EMT in carcinoma metastasis.INTRODUCTION
During metastasis, epithelial tumor cells invade surrounding
extracellular matrix (ECM), disseminate into the systemic circula-
tion, and then establish secondary tumors in distant sites. A
developmental program termed epithelial-mesenchymal transi-
tion (EMT) has been implicated in giving rise to the dissemination
of single carcinoma cells. During EMT, stationary epithelial cells
lose their epithelial characteristics, including adherent junctions
and apical-basal polarity, and acquire a mesenchymal mor-
phology and the ability to migrate and invade (Hay, 1995).
Biochemically, cells switch off the expression of epithelial
markers, such as adherens junction proteins E-cadherin and
catenins, and turn on mesenchymal markers, including vimentin
and fibronectin. Studies using cell culture and tumor xenograft
models show that activation of EMT promotes carcinoma cells
to dissociate from each other and metastasize to distant organs
(Hay, 1995; Kalluri and Weinberg, 2009; Thiery, 2002, 2009).Significance
EMT features are frequently observed in many types of primary
Our findings indicate that reversible EMT likely represents a
onset of metastasis following primary tumor removal is though
organs. Our study raises the possibility that tumor dormancy
revert EMT and proliferate. The dynamic involvement of EMT
be counterproductive in preventing distant metastases when
blocking EMT reversion may prevent dormant tumor cells from
CanHowever, the involvement of EMT in tumor metastasis in vivo
is still hotly debated (Garber, 2008; Ledford, 2011; Tarin et al.,
2005; Thompson et al., 2005). In human carcinoma, although
primary tumors show many morphological and molecular
features of EMT in subpopulations of invasive cells, distant
metastases present an epithelial morphology (Peinado et al.,
2007). This phenomenon contradicts the assumption that activa-
tion of EMT in tumor cells should result in metastases with
a mesenchymal phenotype, therefore casting doubts on the
occurrence of EMT during metastasis. This discrepancy could
be due to the interpretation of the EMT program as a permanent
nonreversible course during tumor metastasis. A reversible EMT
model has been proposed to explain this apparent paradox:
carcinoma cells undergo EMT to invade and disseminate from
the primary tumor; once reaching distant sites, tumor cells
need to revert to an epithelial identity to form macrometastases
(Thiery, 2002). However, this hypothesis has not been attested
in vivo.human carcinoma, but not their corresponding metastases.
key driving force in human carcinoma metastasis. Delayed
t to be due to resurrection of latent carcinoma cells in distant
could be due to the inability of disseminated tumor cells to
in metastasis cautions that therapies inhibiting EMT could
patients already present circulating tumor cells. Instead,
establishing metastases.
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Reversibility of EMT Is Essential for MetastasisThe EMT program is orchestrated through a network of tran-
scription factors, including Twist1 (Yang et al., 2004), Snail1/2
(Batlle et al., 2000; Cano et al., 2000; Hajra et al., 2002), Zeb1/2
(Comijn et al., 2001; Eger et al., 2005), and FOXC2 (Mani et al.,
2007). Our previous study found that Twist1 is a potent inducer
of EMT and invadopodia-mediated ECM degradation (Eckert
et al., 2011; Yang et al., 2004). In mouse and human breast tumor
xenograft models, Twist1 expression can promote tumor metas-
tasis (Yang et al., 2004). Clinical studies have also associated
expression of Twist1 in primary tumors with disease aggressive-
ness and poor survival in many types of human cancers, such as
squamous cell carcinoma, breast cancer, prostate cancer, and
gastric cancer (Eckert et al., 2011; Kallergi et al., 2011; Peinado
et al., 2007; Watson et al., 2007).
Unlike human carcinoma metastases, most established meta-
static tumor cell lines present a permanentmesenchymal pheno-
type (Blick et al., 2008) and cannot be used to address the
dynamic EMT process during tumor metastasis in vivo. Recent
elegant studies using autochthonous mouse tumor models
observed the occurrence of EMT in primary carcinoma, but
how EMT spatiotemporally regulates metastasis has not been
investigated in these models (Hu¨semann et al., 2008; Rhim
et al., 2012). The chemical carcinogenesis mouse skin model
has been shown to recapitulate the multistep process of human
carcinoma progression, including initiation, growth, invasion,
and metastasis (Kemp, 2005; Perez-Losada and Balmain,
2003). At the molecular and genetic levels, the skin carcinogen-
esis model shares strong similarities with a number of carcinoma
in humans, including activating mutations in Ras family mem-
bers, activation of PI3K- and Stat3-mediated signaling path-
ways, elevated expression of transforming growth factor b1
(TGFb1), and activation of the TGFb/Smad signaling pathways
and, at later stages, Trp53 mutations (DiGiovanni, 1992; Kemp,
2005). Importantly, like human squamous cell carcinoma, this
model develops distant metastases with an epithelial mor-
phology in lymph nodes and lungs (Han et al., 2005), making it
a suitable model to study the involvement of EMT in vivo.
Furthermore, extensive studies have shown that expression of
Twist1 in primary human squamous cell carcinoma, including
esophageal cancer (Sasaki et al., 2009; Xie et al., 2009; Yuen
et al., 2007) and head and neck cancer (Ou et al., 2008; Wushou
et al., 2012), correlates with distant metastasis and poor
prognosis. In this study, we investigate the importance of the
dynamic EMT process in metastasis in vivo using the skin carci-
nogenesis model.
RESULTS
Induction of Twist1 Promotes Invasive Carcinoma
Conversion
Previous studies have demonstrated the necessary role of
Twist1 as an inducer of EMT. To understand the contribution of
Twist1 in metastatic carcinoma, we analyzed 99 primary human
carcinomas with patient-matched lymph node metastases for
Twist1 expression. Of the 20 cases with high Twist1 expression
in the primary tumor, we found 16 cases with over 50% drop in
Twist1 levels in the lymph node metastases (Figures S1A and
S1B available online), suggesting Twist1 is activated in the
primary tumor but not distant metastases. To study how726 Cancer Cell 22, 725–736, December 11, 2012 ª2012 Elsevier Incdynamic activation of Twist1 directly impacts carcinoma
progression, we generated skin-specific Twist1 Tet-on inducible
mice by crossing transgenic mice carrying a single copy of a
TetOP-Twist1 transgene with Keratin 5 promoter-driven reverse
tetracycline-controlled transactivator mice (K5-rtTA) (Diamond
et al., 2000). Bitransgenic mice (referred to as K5-Twist1 mice)
showed specific expression of Twist1 protein in the basal
epidermal layer upon doxycycline (dox) treatment (Figure S1C).
Long-term induction of Twist1 alone in K5-Twist1 mice did not
result in visible skin abnormalities (data not shown). To generate
squamous cell carcinoma (SCC), K5-Twist1 mice and control
single transgene littermates were treated with a single dose of
7,12-dimethylbenz[a]anthracene (DMBA) followed by weekly
applications of 12-O-tetradecanoylphorbol-13-acetate (TPA)
for 20 weeks to allow skin tumor development (Abel et al.,
2009; Kemp, 2005; Sun et al., 2007) (Figure 1A). At the end of
TPA treatment, when all mice have developed multiple papil-
lomas, we randomly divided these mice into two groups. One
group of mice received doxycycline in the drinking water to allow
continuous Twist1 expression in K5-positive tumor cells, even if
tumor cells have migrated out of the skin and disseminated
throughout the body. We used this systemic Twist1 induction
group as the model for ‘‘irreversible EMT.’’ The second group
of mice received doxycycline topically on the dorsal skin area
containing papillomas to induce Twist1 only at the primary tumor
site, such that tumor cells would lose Twist1 expression once
they have disseminated from the skin. This local induction of
Twist1 was used as the model for ‘‘reversible EMT’’ (Figures
1A and S1D).
Within 7 days of doxycycline treatment through either oral or
topical routes, papillomas on the K5-Twist1 mice began to
invaginate into the skin and converted to SCCs at similar rates
in both groups (Figures 1B and 1C). By three weeks, both groups
of K5-Twist1 mice presented over 3-fold higher conversion
frequencies than their control littermates (Figure 1C). Impor-
tantly, induction of Twist1 by oral or topical doxycycline resulted
in similar conversion rates and frequencies of papillomas to
SCCs (52% for oral treatment versus 40% for topical treatment;
Figures 1C and 1D), demonstrating similar efficacy of Twist1
induction at the primary site using both doxycycline delivery
methods. Histological analysis confirmed that papillomas have
converted to poorly differentiated SCCs, with many regions pre-
senting a spindle-cell phenotype in both groups of K5-Twist1
mice, while the naturally converted SCCs in the control group
showed a well- to moderately differentiated epithelial mor-
phology (Figure 1E). In Twist1-induced SCCs, tumor cells
invaded through the underlying basement membrane, demon-
strating a role of Twist1 in matrix degradation (Figure 1F).
Together, these data indicate that Twist1 is sufficient to promote
invasive carcinoma progression in vivo.
Reversible Induction of Twist1 Promotes Carcinoma
Metastasis
To understand how irreversible versus reversible induction of
Twist1 impacts metastasis, we examined individual mice for
distant metastases by macroscopic and histological analysis.
Starting at 5 weeks after doxycycline induction, mice with heavy
metastasis burden were sacrificed together with mice in the
comparison groups, and all mice were terminated by 8 weeks..
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Figure 1. Induction of Twist1 Promotes Invasive Carcinoma Conversion
(A) A schematic of the DMBA/TPA skin tumor model and two doxycycline (dox) induction approaches in K5-Twist1 mice.
(B) Representative images of tumor lesions in control and doxycycline-treated K5-Twist1 mice over time. Control mice are single transgene littermates that
received oral or topical doxycycline.
(C) Graph of conversion rates from papillomas to SCCs over time for a representative cohort ± SEM at each time point.
(D) Scatter plot of SCC conversion frequency in control and doxycycline-treated K5-Twist1 mice. Each dot represents one mouse, and the bar represents the
mean of each group. *p < 0.0001 compared to control group, Student’s t test.
(E) Histologic sections of tumors stained with hematoxylin and eosin. Papillomas have well-defined cellular organization, whereas control SCCs are well- to
moderately differentiated. In contrast, doxycycline-treated tumors are disorganized and poorly differentiated. Bar = 50 mm.
(F) Frozen tumor sections were costained for tumor cells (K5, green), basement membrane (laminin 5, red), and nuclei stain (blue) to examine the breachment of
basement membrane by tumor cells. Bar = 50 mm.
See also Figure S1.
Cancer Cell
Reversibility of EMT Is Essential for MetastasisConsistent with published data, 27%–33% of control SCC-
bearing mice developed distant metastases in the lymph node
and/or the lung (Abel et al., 2009; Kemp, 2005). Strikingly, 12
out of 14 K5-Twist1 mice (86%) receiving topical doxycyclineCandeveloped distant metastases. In contrast, only three out of 13
K5-Twist1 mice (23%) receiving oral doxycycline developed
distant metastases (Figure 2A). K5-Twist1 mice receiving topical
doxycycline also developed significantly more metastaticcer Cell 22, 725–736, December 11, 2012 ª2012 Elsevier Inc. 727
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Figure 2. Reversible Induction of Twist1 Promotes Carcinoma Metastasis
(A) A histogram showing metastasis frequencies in control and K5-Twist1 mice group receiving oral or topical doxycycline. The fraction of mice developing
metastases in individual groups is represented above each bar. Fisher’s exact test analysis was performed to determine statistical significance.
(B) An event was defined as a tumor nodule in an individual lymph node and/or the presence of at least a single nodule in the lung tissue. Each dot represents
a single mouse. Student’s t test statistical analysis was performed to compare average events per group.
(C) Representative images of tumor sections costained for Twist1 (brown) and K5 (green). Paraffin-embedded tumor sections were stained for Twist1 using
immunohistochemistry (brown) followed by immunofluorescent staining for K5 (green) on the same section to identify tumor cells. Bar = 50 mm.
Cancer Cell
Reversibility of EMT Is Essential for Metastasislesions per mouse than mice receiving oral doxycycline, high-
lighting the drastic difference in metastasis incidences between
these two groups (Figure 2B). It is also important to note that this
difference is not due to nonspecific effects of doxycycline, since
control mice receiving oral or topical doxycycline presented
similar metastasis frequencies (Figures 2A and 2B).
We next examined the expression of Keratin 5 and Twist1 in
the primary tumors and metastatic nodules. We found that all
skin tumor cells express Keratin 5 both with and without Twist1
induction, suggesting that Keratin 5 can be used to specifically
mark skin tumor cells in this model. Importantly, we detected
robust nuclear Twist1 expression in the primary tumors following
both oral and topical doxycycline treatment; in contrast, all
distant metastatic lesions showed no Twist1 expression (Fig-
ure 2C). Together, these results indicate that only reversible,
but not irreversible, induction of Twist1 significantly promotes
distant metastasis.728 Cancer Cell 22, 725–736, December 11, 2012 ª2012 Elsevier IncTwist1 Regulates EMT in a Reversible Fashion during
Metastasis In Vivo
To understand whether Twist1 indeed regulates EMT in a revers-
ible manner during metastasis, we examined both primary
tumors and metastatic nodules for the expression of Twist1
and key EMT markers. In control mice, the naturally converted
SCCs showed strong expression of epithelial markers, including
E-cadherin, b-catenin, and g-catenin (Figures 3A–3C and S2A)
and no expression of mesenchymal marker vimentin in the tumor
cells (Figure 3D). Primary tumors from K5-Twist1 mice receiving
either oral or topical doxycycline presented diminished epithelial
markers and strong vimentin expression, indicating that Twist1
can effectively induce EMT in primary tumors (Figures 3, S2A,
and S2B). In contrast, all corresponding distant metastases in
the topical induction group present an epithelial morphology
with no vimentin expression and strong E-cadherin staining
(Figures 3C, 3D, and S2C). The fact that topical induction of.
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Figure 3. Twist1 Regulates EMT in a Reversible Fashion during Metastasis
(A) Primary and metastatic tumor samples were costained for E-cadherin (red) and K5 (green) to identify tumor cells undergoing EMT. Bar = 50 mm.
(B) The relative E-cadherin levels in K5+ tumor cells were quantified in individual tumor samples from (A). Values were normalized to control samples and plotted
on a histogram ± SEM. Student’s t test statistical analysis was performed.
(C) Representative images of tumor sections from control and K5-Twist1 mice costained for Twist1 (brown) and E-cadherin (green) expression. Boxed regions
highlight areas of Twist1-positive tumor cells with disrupted or absent E-cadherin expression. Bar = 50 mm.
(D) Representative images of tumor sections from control and K5-Twist1 mice costained for Twist1 (brown) and vimentin (green) expression. Arrows indicate
Twist1-positive tumor cells that express vimentin. Bar = 25 mm.
See also Figure S2.
Cancer Cell
Reversibility of EMT Is Essential for MetastasisTwist1 drastically increased metastasis incidence and that
distant metastases presented an epithelial phenotype indicates
that ‘‘reversible EMT’’ can effectively promote tumor metastasis.
To our surprise, while oral doxycycline induction of Twist1
reduced E-cadherin expression and induced EMT in primaryCantumors in all 13 mice (Figure 3), the rare metastatic nodules
developed in three mice also presented an epithelial morphology
(Figure S2D). Immunostaining analyses of these metastases
showed strong E-cadherin along with weak Twist1 expression
in the tumor cells (Figure S2E), suggesting that these rarecer Cell 22, 725–736, December 11, 2012 ª2012 Elsevier Inc. 729
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Figure 4. Activation of EMTPromotes Tumor
Cell Intravasation
(A) Representative image of circulating tumor cells
(CTCs). CTCs are defined as cells that are CD45
(red) and CK+ (green) and present irregular nuclear
shape (arrows). Inset shows magnified irregular
nucleus in CTC. Bar = 10 mm.
(B) Quantification of CTCs in K5-Twist1 mice prior
to doxycycline treatment (pre dox) in control mice
and K5-Twist1 mice receiving oral and topical
doxycycline. The percentages of CTCs among all
nucleated cells were plotted on a histogram ± SEM.
Student’s t test statistical analysis was performed.
(C) CTCs from control and doxycycline-treated
K5-Twist1 mice were examined for Twist1 expres-
sion. Representative images of CTCs costained for
Twist1 (green), CD45 (red), and nuclei (blue).
Arrows represent CTCs that are Twist1-positive;
arrowheads represent CTCs that are Twist1-
negative. Bar = 10 mm.
(D) Representative images of CTCs costained for
E-cadherin (green), CD45 (red), and nuclei (blue).
Arrowheads represent CTCs that are E-cadherin-
negative. All CTCs show no E-cadherin expression.
Bar = 10 mm.
(E) Representative images of CTCs stained for
vimentin (green), CD45 (red), and nuclei (blue).
Arrows represent CTCs that are vimentin-positive;
arrowheads represent CTCs in the control litter-
mates that are vimentin-negative. Bar = 10 mm.
See also Figure S3.
Cancer Cell
Reversibility of EMT Is Essential for Metastasismetastases are likely due to additional selective genetic and/or
epigenetic changes that circumvent Twist1-induced EMT to
allow the formation of epithelial metastases. Together, these
results strongly support a requirement for the reversion of EMT
in forming distant metastases in vivo.
Activation of EMT in Primary Tumors Promotes
Intravasation
To successfully metastasize, carcinoma cells need to complete
distinct steps, including invasion, intravasation, extravasation,
and growth at distant sites. To investigate how activation of
EMT impacts tumor cell intravasation into the blood circulation,
we isolated circulating tumor cells (CTCs) from peripheral blood
of K5-Twist1 and control mice. CTCs are defined as cells that are
CD45 and pan-cytokeratin (CK)+ and present irregular nuclear
shape (Figure 4A). The percentages of CTCs in the blood730 Cancer Cell 22, 725–736, December 11, 2012 ª2012 Elsevier Inc.increased over 2-fold in K5-Twist1 mice
following oral or topical doxycycline treat-
ment, compared to samples from control
mice or from K5-Twist1 mice prior to
doxycycline treatment (Figure 4B). Impor-
tantly, upon Twist1 induction, these CTCs
were positive for Twist1 and mesen-
chymal marker vimentin, but negative
for epithelial markers E-cadherin and
b-catenin (Figures 4C–4E and S3), indi-
cating an EMT phenotype in the CTCs.
This result is consistent with studies
showing that CTCs from human cancerpatients present many features of EMT (Hou et al., 2011; Kallergi
et al., 2011; Min et al., 2009) and that the presence of CTCs in
human squamous cell carcinoma cancer patients is associated
with distant metastasis and poor survival (Jatana et al., 2010; Pa-
jonk et al., 2001; Winter et al., 2009). Our data show that both
reversible and irreversible activation of EMT are equally effective
in promoting tumor cell intravasation, and therefore the ability to
disseminate is not the cause of different metastasis rates.
Activation of EMT Promotes Tumor Cell Extravasation
To examine the impact of EMT on tumor cell extravasation in
distant organs, we isolated primary tumor cells from a K5-Twist1
mouse and treated them in culture with doxycycline for 7–
11 days to induce Twist1 and EMT (Figures 5A and S4). These
cells were then labeled with a fluorescent cell tracker and
injected via tail vein into wild-type mice receiving doxycycline
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Figure 5. Activation of EMT Promotes Tumor Cell Extravasation
(A) A schematic of the experimental lung metastasis design.
(B) Confocal images of tumor cell (red) extravasation from lung vasculature (green). Bar = 20 mm.
(C) Quantification of tumor cell extravasation at 36 hr post tail vein injection. The number of tumor cells inside or outside of the vasculature was counted and then
divided by the total number of cells assayed (n = 28–32 cells per group). The percentage of tumor cells inside (intravascular) or outside (extravascular) of the vessel
was plotted on a stacked bar graph. *p < 0.0001 as determined by Fisher’s exact test, compared to control group I.
(D and E) Images of lung tissues and quantification of average lung nodules per mouse ± SEM 4 weeks after tail vein injection. Student’s t test statistical analysis
was performed.
See also Figure S4.
Cancer Cell
Reversibility of EMT Is Essential for Metastasisor no doxycycline in drinking water, mimicking ‘‘irreversible’’
versus ‘‘reversible’’ EMT, respectively. The parental primary
tumor cells were also injected as the ‘‘no EMT’’ control (Fig-
ure 5A). At 36 hr after injection, we quantified the number of
tumor cells extravasated from the lung vasculature. While only
20% of ‘‘no EMT’’ control cells (Group I) extravasated out of
the lung vasculature, induction of Twist1 promoted 75%of tumor
cells to extravasate under both ‘‘irreversible’’ and ‘‘reversible’’
conditions (Group II and III) (Figures 5B and 5C). Supporting
these results, 4 weeks after tail vein injection, the ‘‘no EMT’’
group (Group I) resulted in very few lung metastases compared
to the other two groups (Group II and III) (Figures 5D and 5E).
This strongly indicates that activation of Twist1 and EMT is crit-
ical to promote extravasation. Furthermore, consistent withCanprevious studies (Cameron et al., 2000; Mendoza et al., 2010),
tumor cells in circulation can extravasate from the blood within
1–2 days, much shorter than the time required for EMT reversion
(5 days). Therefore, these data also show that reversible
activation of EMT in tumor cells can persist long enough to allow
effective extravasation from the vasculature into distant organs
before EMT reversion.
Reversion of EMT Promotes Colonization in Distant
Sites
Since reversible and irreversible activation of EMT can both
effectively promote local invasion, intravasation, and extra-
vasation, the ability to grow in distant organs is likely to be the
critical step regulated by the reversion of EMT. Because cellcer Cell 22, 725–736, December 11, 2012 ª2012 Elsevier Inc. 731
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Figure 6. Reversion of EMT Promotes Colonization in Distant Sites
(A) Representative images of tumor sections costained with Twist1 (green), Ki67 (red), and nuclear stain (blue). Tumor sections from control and doxycycline-
treated K5-Twist1 mice were costained for Twist1 and Ki67 to identify proliferation tumor cells. Bar = 50 mm.
(B and C) Relative levels of Twist1 and Ki67 expression in primary tumors from control and doxycycline-treated K5-Twist1 mice. Values were plotted on a
histogram ± SEM. Student’s t test statistical analysis was performed. n = tumor samples per group.
(D–F) Representative images of lung sections costained for K5 (green), Twist1 (brown) or Ki67 (brown), and quantification of Twist1 and Ki67 expression at 7 days
post tail vein injection. Values were plotted on a histogram ± SEM. Student’s t test statistical analysis was performed. n = mice per group.
Cancer Cell
Reversibility of EMT Is Essential for Metastasisproliferation is essential for establishing macrometastases and
EMT-inducing factors are shown to reduce cell proliferation (Ev-
dokimova et al., 2009; Vega et al., 2004), we analyzed the effect
of Twist1 on tumor cell proliferation. Indeed, individual primary
tumor cells expressing Twist1 showed very low to nondetectable
expression of the proliferation marker Ki67 (Figure 6A). Tumor
cell proliferation appeared to be negatively correlated with
Twist1 expression (Figures 6B and 6C). To demonstrate that
reversion of EMT to promote cell proliferation at distant sites is
the essential step in establishing early metastatic colonies, we732 Cancer Cell 22, 725–736, December 11, 2012 ª2012 Elsevier Incperformed experimental lung metastasis studies, as described
in Figure 5A, and examined cell proliferation and Twist1 expres-
sion in early metastatic lesions in the lung (7 days postinjection).
Remarkably, early metastatic colonies showed strong positive
Ki67 expression and low Twist1 expression under ‘‘reversible’’
EMT condition, while ‘‘irreversible’’ EMT resulted in colonies
with high Twist1 expression and low Ki67 (Figures 6D–6F). This
demonstrates that reversion of EMT promotes proliferation and
establishment of early metastatic colonies in distant sites.
Consistent with this result, 4 weeks after tail injection, mice in.
Figure 7. Reversible EMT Model for Tumor
Metastasis
During tumor progression, local microenviron-
mental cues in the primary tumor activate the EMT
program. This triggers local tumor cell invasion
and intravasation into the blood vessels. Circu-
lating tumor cells maintain an EMT phenotype and
travel to a distant site, after which the cells
extravasate into the tissue parenchyma. The loss
of EMT activating signals is essential for tumor
cells to reverse phenotype and proliferate to form
macrometastases.
Cancer Cell
Reversibility of EMT Is Essential for Metastasisthe reversible EMT group (Group III) developed significantlymore
metastatic lung nodules than the irreversible group (Group II)
(Figures 5D and 5E). Combined with our results above, these
data show that disseminated tumor cells need to turn off Twist1
to reverse the EMT program, thus allowing proliferation to facil-
itate colonization in distant sites.
DISCUSSION
The in vivo role of EMT in tumor metastasis has been under
intense debate, due to conflicting observations in human primary
carcinoma and their corresponding distant metastases. In
a spontaneous squamous cell carcinoma mouse model, we
demonstrate the dynamic requirement of EMT in tumor metas-
tasis: activation of EMT promotes local tumor invasion, intrava-
sation, and extravasation of the systemic circulation; while
reversion of EMT is essential to establish macrometastases (Fig-
ure 7). This mouse model mimics many genetic, molecular, and
cellular features of human carcinoma. Our study, together with
other clinical studies in breast, ovarian, and prostate cancers
(Chao et al., 2010; Hudson et al., 2008; Hugo et al., 2007), indi-
cates that EMT is activated in many types of primary human
carcinoma, but not in their distant metastases. Therefore, the
reversible EMT model demonstrated in the mouse squamous
cell carcinoma is likely a general principle applicable to human
carcinoma metastasis.
The ‘‘reversible’’ EMTmodel implies a level of cellular plasticity
in the tumor cells. In other words, it is rather unlikely that genes
involved in the EMT program will be permanently altered on the
genome level, thus being unable to revert in distant sites during
metastasis. This is supported by the fact that key EMT-inducing
transcription factors and other key genes involved in the EMT
pathway have not been reported to be prime targets for genomic
deletion or mutation in various human cancer genome
sequencing and mouse tumor model studies. Instead, the EMT
program is largely controlled at the transcriptional and transla-
tional level in response to various proinvasion signals in the local
tumor microenvironment, such as hypoxia, inflammation, and
nutrient conditions. TGFb1, one such EMT-inducing signal
from tumor stroma, has been examined for its role in promotingCancer Cell 22, 725–736, Dinvasion and metastasis in the skin
carcinogenesis model. Interestingly, the
inducible TGFb1 mice used in the study
required topical induction to activate the
TGFb1 transgene. In these mice, topicalactivation of TGFb1 signaling promoted invasive SCCs with
spindle cell morphology and resulted in distant metastases
with epithelial characteristics (Han et al., 2005; Weeks et al.,
2001). These results could also be due to tumor cells undergoing
a reversible EMT to form epithelial metastases, as demonstrated
in our Twist1 mouse model.
An alternative model of EMT in tumor metastasis proposes
that epithelial tumor cells can seed metastasis without under-
going EMT in the presence of mesenchymal tumor cells that
have undergone EMT (Celia`-Terrassa et al., 2012; Tsuji et al.,
2008). Our results, showing that circulating tumor cells express
no E-cadherin (Figure 4D), would argue that these epithelial cells
might have undergone a transient EMT, perhaps in response to
an inducing signal from coexisting mesenchymal tumor cells in
primary tumors to metastasize.
The transient nature of EMT requires a delicate balance
between the maintenance and loss of epithelial traits to promote
efficient metastasis in vivo. In culture, epithelial cells undergoing
a complete EMT lose epithelial markers, including cytokeratin
expression. Our data suggests carcinoma cells in vivo may
only need to undergo a partial EMT for dissemination, as evident
by detectable cytokeratin expression in the CTCs (Figure 4). This
is supported by observations that human cytokeratin-positive
CTCs also present an EMT signature (Hou et al., 2011; Kallergi
et al., 2011; Min et al., 2009; Rhim et al., 2012). A partial EMT
would be sufficient to promote tumor cell dissemination, but
also facilitate disseminated mesenchymal tumor cells to quickly
revert to an epithelial phenotype for proliferation and coloniza-
tion in distant organs.
The ability to proliferate at distant sites is essential for the
establishment of early metastatic lesions. Previous studies
have shown that EMT-inducing factors can reduce cell prolifera-
tion in various tumor cells (Bierie and Moses, 2006; Evdokimova
et al., 2009; Vega et al., 2004). Independent studies also found
that invasive tumor cells also present a gene signature that impli-
cates decreased cellular proliferation and increased motility
(Goswami et al., 2004; Wang et al., 2004). Our study demon-
strates that Twist1 expression decreased cell proliferation in vivo
and turning off Twist1 at distant sites promoted metastatic
growth, therefore suggesting that tumor cells need to toggleecember 11, 2012 ª2012 Elsevier Inc. 733
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Reversibility of EMT Is Essential for Metastasisproliferation andmigration to achieve efficient metastasis. This is
consistent with a recent report that reversion of EMT in MDA-
MB-231 cells is associated with increased proliferation during
lung colonization (Gao et al., 2012). However, given that coloni-
zation, a rate-limiting step in metastasis, has been shown to
require numerous cellular and molecular events to accomplish
(Chambers et al., 2002; Luzzi et al., 1998; Sugarbaker, 1993;
Weiss, 1990), it is evident that reversion of EMT to increase prolif-
eration in distant sites alone is not sufficient for colonization.
Indeed, the results from our spontaneous skin tumor model
show that the number of metastatic lesions in individual mice
is still much lower (average two lesions per mouse) compared
to the abundant circulating tumor cells detected in the blood
upon Twist1 induction. Therefore, future studies are needed to
identify additional molecular events that contribute to coloniza-
tion in this tumor model.
Cancer patients can develop metastases from dormant tumor
cells years after primary tumor resection (Chambers et al., 2002;
Goss and Chambers, 2010; Meng et al., 2004). Although it is
technically challenging to detect single dormant tumor cells in
distant organs in our spontaneous tumor model and in cancer
patients, both our study and several clinical studies found that
circulating tumor cells in the blood present many molecular
features of EMT (Hou et al., 2011; Kallergi et al., 2011; Min
et al., 2009; Rhim et al., 2012). Therefore, our study raises the
possibility that dormant tumor cells are in an EMT state and
need to revert EMT to regain proliferation. Therapeutic agents
that inhibit EMT have been proposed as a treatment option
against tumor metastasis (Garber, 2008). The transient nature
of EMT in carcinoma metastasis cautions that such an approach
alone could be counterproductive and promote metastatic colo-
nization when patients already present circulating tumor cells.
Instead, inhibiting the reversion of EMT could be a logical
approach to prevent resurrection of dormant tumor cells.
EXPERIMENTAL PROCEDURES
Generation of Inducible Twist1 Mice and Tumor Model
All animal care and experiments were approved by the Institutional Animal
Care and Use Committee of the University of California, San Diego. TetOP-
Twist1 mice were generated using a site-specific single copy integration
strategy (Beard et al., 2006). Mice were backcrossed over nine generations
onto the FVB/N strain. Skin-specific inducible Twist1 mice were generated
by crossing TetOP-Twist1 mice with K5-rtTA mice (Diamond et al., 2000)
(kindly provided by Dr. Stuart Yuspa, NCI, Bethesda, MD). The DMBA/TPA
multistage chemical carcinogenesis model was performed as previously
described (Abel et al., 2009; Sun et al., 2007). Briefly, 20 mg of DMBA was
applied topically on the dorsal skin of transgenic mice. Mice were then treated
with 12.5 mg of TPA twice a week for 20 weeks. Papilloma-bearing mice were
then randomly divided to receive doxycycline (2 mg/ml) in the drinking water or
topically on the dorsal skin.
The conversion rate from papilloma to squamous cell carcinoma (SCC) was
calculated by dividing the number of ulcerated tumors by the total number of
papillomas plus ulcerated tumors per mouse. Ulcerated tumors were defined
as nodules that were previously papillomas and have invaginated into the
dorsal skin. Mice with heavy metastasis burden were sacrificed together
withmice in the comparison groups, and all micewere examined formacrome-
tastases. A metastatic event was defined as a tumor nodule in an individual
lymph node and/or the presence of at least a single nodule in the lung tissue.
Biochemistry and Immunohistological Staining and Analysis
Paraffin-embedded tumor sections were stained with a mouse anti-Twist1
antibody (Santa Cruz Biotech, Santa Cruz, CA), rabbit anti-Keratin 5 antibody734 Cancer Cell 22, 725–736, December 11, 2012 ª2012 Elsevier Inc(K5, Covance, Princeton, NJ), rabbit anti-pan-cytokeratin antibody (pan-CK,
Abcam, Cambridge, MA), rabbit anti-E-cadherin (Abcam), mouse anti-b-cate-
nin (BD Biosciences, San Diego, CA), mouse anti-g-catenin (BD Biosciences),
rabbit anti-vimentin (GeneTex, Irvine, CA), or rabbit anti-Ki67 antibody
(Abcam). Endogenous mouse antigen was blocked using Mouse on Mouse
blocking agent (Vector labs, Burlingame, CA). Immunohistochemistry was
performed using the ABC kit (Vector labs) and developed with 3,30 diamino-
benzidine chromogen (Vector labs). Frozen tumor sections were stained
with a chicken anti-K5 antibody (gift from Dr. Colin Jamora) and rabbit anti-
laminin 5 antibody (gift from Dr. Monique Aumailley) to identify K5 tumor cells
and basement membranes. Alexafluor dyes (Invitrogen, Carlsbad, CA) conju-
gated to the appropriate species were used as secondary antibodies. Hoechst
33258 dye or DAPI were used for nuclear stain. Western blot analysis for
Twist1, E-cadherin, b-catenin, and glyceraldehyde-3-phosphate dehydroge-
nase protein expression was performed as previously described (Eckert
et al., 2011).
Images were collected using an Olympus FV-1000 confocal microscope or
Nikon E600 upright microscope. For quantification of Twist1 and Ki67 expres-
sion, at least three fields were collected for each tumor and at least five tumors
from each groupwere examined. Twist1-positive cells, Ki67-positive cells, and
the total number of cells (nuclear stain positive) from each field were counted
using Volocity software (PerkinElmer, Waltham,MA). For quantification of rela-
tive E-cadherin levels, images were analyzed for E-cadherin expression by
measuring the threshold level of staining using Image J software (National
Institutes of Health), then divided by the area of positive K5 staining to
calculate relative E-cadherin levels in tumor regions. Values were normalized
to E-cadherin levels in control tumors.
Circulating Tumor Cell Staining and Analysis
Peripheral blood was obtained from tumor-bearing mice via submandibular
bleeding or intracardiac puncture at the termination of the experiment. Red
blood cells (RBCs) were removed by incubating whole blood in RBC lysis
solution. Remaining cells were spun down and fixed in 4% paraformaldehyde.
Cells were then spun onto slides using a cytospin and stained with rat anti-
CD45 (BD Biosciences) and rabbit anti-pan-CK (Abcam) antibodies, followed
by DAPI nuclear stain. Circulating tumor cells (CTCs) were identified as irreg-
ularly shaped nucleated cells that were CD45-negative, CK-positive cells. All
cells in at least five high-powered fields were counted, and the relative
percentage of CTCs was calculated and plotted on a histogram.
Experimental Lung Metastasis Assay
Primary inducible Twist1 skin tumor cells were isolated from a tumor-bearing
K5-Twist1 mouse according to manufacturer’s protocol for Defined Keratino-
cyte Serum-Free Media protocol (Invitrogen). Briefly, tumors were removed
and incubated in PBS with 2X antibiotic cocktail solution (Invitrogen) for
1–2 hr at 4C. Tumors were transferred to dispase solution supplemented
with 2X antibiotic cocktail solution and incubated at 4C overnight. Tumors
were then minced in 0.5% Trypsin solution and incubated at 37C for about
15min. A soybean trypsin inhibitor (Invitrogen) was used to stop the trypsiniza-
tion. Cells weremaintained in serum-free keratinocytemedia. To induce Twist1
in culture, doxycycline (1 mg/ml) was added into the media. After 7–11 days,
1–1.5 3 106 cells were injected via tail vein injection into mice receiving no
doxycycline water or 2 mg/ml doxycycline water. Mice were monitored and
euthanized when breathing appeared difficult. Lung tissue was perfused with
and fixed in 4% paraformaldehyde. Tumor nodules on the surface of every
lung lobe were counted, and the numbers were plotted on a histogram. For
tumor cell proliferation analysis, mice were euthanized 7 days postinjection
of cells. Lung tissue was perfused and embedded in paraffin. Tissue sections
were stained for K5, Twist1, and Ki67, as previously mentioned.
For tumor cell extravasation analysis, cells were labeled with CellTracker-
Red (Invitrogen) according to manufacturer’s recommendation. A total of
1–1.5 3 106 cells were injected into mice via tail vein, and mice were eutha-
nized after 36 hr. To label lung vasculature, mice were injected with Fluores-
cein-labeled Lycopersicon Esculentum Lectin (Vector Labs) 30 min prior to
euthanasia. Thick lung tissue sections were obtained by manually slicing the
tissue and were then mounted on slides for viewing. Confocal z-stack images
were obtained using an Olympus FV-1000 microscope and analyzed using
FluoView (Olympus) and Image J software..
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Tissue microarray (TMA) of 99 human breast carcinoma and matched metas-
tases were purchased fromUSBiomax Inc. The TMA contained human tissues
obtained with informed consent according to US federal law and are exempt
from Institutional Review Board review by the University of California, San
Diego Human Research Protections Program. Staining for Twist1 and cytoker-
atin was performed as described above. All samples were analyzed for Twist1
expression, and patient samples were considered positive for Twist1 expres-
sion only if >10% of tumor cells in the primary tumor stained positive for
nuclear Twist1. Out of 99 matched samples, only 20 samples met our criteria
for being positive for Twist1. Cells were counted using the cell counter function
in Image J software.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism Software (La Jolla,
CA). Student’s t test was applied for comparisons between two groups. The
Fisher’s exact test was applied to analyze the metastasis frequency and tumor
cell extravasation rate using a contingency table. The one-tailed exact bino-
mial test was performed for statistical analysis of Twist1 expression in human
breast cancer TMA.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this
article online at http://dx.doi.org/10.1016/j.ccr.2012.09.022.
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